Iclepertin
Iclepertin[edit | edit source]
Iclepertin is a novel investigational drug that is being studied for its potential use in the treatment of cognitive impairment associated with schizophrenia and other neuropsychiatric disorders. It is classified as a glycine transporter 1 (GlyT1) inhibitor, which works by modulating the levels of glycine in the brain, thereby enhancing NMDA receptor function.
Mechanism of Action[edit | edit source]
Iclepertin functions by inhibiting the glycine transporter 1 (GlyT1), which is responsible for the reuptake of glycine from the synaptic cleft. By blocking GlyT1, iclepertin increases the availability of glycine, an important co-agonist of the NMDA receptor. This enhancement of NMDA receptor activity is thought to improve cognitive processes such as learning and memory, which are often impaired in conditions like schizophrenia.
Clinical Development[edit | edit source]
Iclepertin is currently undergoing clinical trials to evaluate its efficacy and safety in patients with cognitive deficits. Early studies have shown promise, indicating potential benefits in cognitive function without significant adverse effects. The drug is being developed by pharmaceutical companies with a focus on addressing unmet needs in the treatment of cognitive impairments.
Potential Applications[edit | edit source]
The primary focus of iclepertin's development is for the treatment of cognitive impairment in schizophrenia. However, its mechanism of action suggests that it may also be beneficial in other conditions characterized by NMDA receptor hypofunction, such as Alzheimer's disease and other forms of dementia.
Side Effects and Safety[edit | edit source]
As with any investigational drug, the safety profile of iclepertin is being closely monitored in clinical trials. Common side effects observed in studies include mild gastrointestinal disturbances and headache. Long-term safety data are still being collected to ensure the drug's safety for chronic use.
Future Directions[edit | edit source]
Research is ongoing to better understand the full potential of iclepertin in treating cognitive impairments. Future studies may explore its use in combination with other therapies, as well as its effects in different patient populations.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
